Literature DB >> 34262063

A system biology approach based on metabolic biomarkers and protein-protein interactions for identifying pathways underlying schizophrenia and bipolar disorder.

Md Altaf-Ul-Amin1, Kazuhisa Hirose2, João V Nani3,4, Lucas C Porta3, Ljubica Tasic5, Shaikh Farhad Hossain2, Ming Huang2, Naoaki Ono2, Mirian A F Hayashi6,7, Shigehiko Kanaya2.   

Abstract

Mental disorders (MDs), including schizophrenia (SCZ) and bipolar disorder (BD), have attracted special attention from scientists due to their high prevalence and significantly debilitating clinical features. The diagnosis of MDs is still essentially based on clinical interviews, and intensive efforts to introduce biochemical based diagnostic methods have faced several difficulties for implementation in clinics, due to the complexity and still limited knowledge in MDs. In this context, aiming for improving the knowledge in etiology and pathophysiology, many authors have reported several alterations in metabolites in MDs and other brain diseases. After potentially fishing all metabolite biomarkers reported up to now for SCZ and BD, we investigated here the proteins related to these metabolites in order to construct a protein-protein interaction (PPI) network associated with these diseases. We determined the statistically significant clusters in this PPI network and, based on these clusters, we identified 28 significant pathways for SCZ and BDs that essentially compose three groups representing three major systems, namely stress response, energy and neuron systems. By characterizing new pathways with potential to innovate the diagnosis and treatment of psychiatric diseases, the present data may also contribute to the proposal of new intervention for the treatment of still unmet aspects in MDs.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34262063     DOI: 10.1038/s41598-021-93653-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  53 in total

1.  Metabolomics and lipidomics analyses by 1H nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis.

Authors:  Ljubica Tasic; João G M Pontes; Michelle S Carvalho; Guilherme Cruz; Carolines Dal Mas; Sumit Sethi; Mariana Pedrini; Lucas B Rizzo; Maiara Zeni-Graiff; Elson Asevedo; Acioly L T Lacerda; Rodrigo A Bressan; Ronei Jesus Poppi; Elisa Brietzke; Mirian A F Hayashi
Journal:  Schizophr Res       Date:  2016-12-29       Impact factor: 4.939

2.  Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post- hoc analysis of a randomized double-blind placebo-controlled trial.

Authors:  Mehar G Kang; Hong Qian; Kamyar Keramatian; Trisha Chakrabarty; Gayatri Saraf; Raymond W Lam; Hubert Wong; Lakshmi N Yatham
Journal:  Aust N Z J Psychiatry       Date:  2019-12-17       Impact factor: 5.744

3.  The schizophrenia and bipolar twin study in Sweden (STAR).

Authors:  Viktoria Johansson; Christina M Hultman; Isabelle Kizling; Lennart Martinsson; Jacqueline Borg; Anna Hedman; Tyrone D Cannon
Journal:  Schizophr Res       Date:  2018-08-16       Impact factor: 4.939

Review 4.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

5.  Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative.

Authors:  Kathleen R Merikangas; Robert Jin; Jian-Ping He; Ronald C Kessler; Sing Lee; Nancy A Sampson; Maria Carmen Viana; Laura Helena Andrade; Chiyi Hu; Elie G Karam; Maria Ladea; Maria Elena Medina-Mora; Yutaka Ono; Jose Posada-Villa; Rajesh Sagar; J Elisabeth Wells; Zahari Zarkov
Journal:  Arch Gen Psychiatry       Date:  2011-03

Review 6.  Bipolar disorder.

Authors:  Iria Grande; Michael Berk; Boris Birmaher; Eduard Vieta
Journal:  Lancet       Date:  2015-09-18       Impact factor: 79.321

7.  GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells.

Authors:  Mei-Ling Liu; Peng Zheng; Zhao Liu; Yi Xu; Jun Mu; Jing Guo; Ting Huang; Hua-Qing Meng; Peng Xie
Journal:  Mol Biosyst       Date:  2014-07-29

8.  Common and distinct structural features of schizophrenia and bipolar disorder: The European Network on Psychosis, Affective disorders and Cognitive Trajectory (ENPACT) study.

Authors:  Eleonora Maggioni; Benedicto Crespo-Facorro; Igor Nenadic; Francesco Benedetti; Christian Gaser; Heinrich Sauer; Roberto Roiz-Santiañez; Sara Poletti; Veronica Marinelli; Marcella Bellani; Cinzia Perlini; Mirella Ruggeri; A Carlo Altamura; Vaibhav A Diwadkar; Paolo Brambilla
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

9.  Post-mortem molecular profiling of three psychiatric disorders.

Authors:  Ryne C Ramaker; Kevin M Bowling; Brittany N Lasseigne; Megan H Hagenauer; Andrew A Hardigan; Nicholas S Davis; Jason Gertz; Preston M Cartagena; David M Walsh; Marquis P Vawter; Edward G Jones; Alan F Schatzberg; Jack D Barchas; Stanley J Watson; Blynn G Bunney; Huda Akil; William E Bunney; Jun Z Li; Sara J Cooper; Richard M Myers
Journal:  Genome Med       Date:  2017-07-28       Impact factor: 11.117

Review 10.  Schizophrenia.

Authors:  Michael J Owen; Akira Sawa; Preben B Mortensen
Journal:  Lancet       Date:  2016-01-15       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.